|Bid||36.530 x 38800|
|Ask||36.540 x 1000|
|Day's Range||36.395 - 36.635|
|52 Week Range||32.320 - 39.430|
|PE Ratio (TTM)||10.15|
|Earnings Date||Jul 31, 2018|
|Forward Dividend & Yield||1.36 (3.74%)|
|1y Target Est||39.86|
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
After moving dangerously close to the tipping point on Tuesday, the market got something of a reprieve with Wednesday’s action. FANG stocks Facebook (NASDAQ:FB) and Netflix (NASDAQ:NFLX) both moved to record highs yesterday, pulling the rest of the market up with them.
In this article I am going to calculate the intrinsic value of Pfizer Inc (NYSE:PFE) by taking the expected future cash flows and discounting them to their present value. ThisRead More...
Xi Jinping has enlisted foreign CEOs to help China in its trade showdown with the US. About 20 multinational executives, including representatives from several American companies, met the Chinese president and top officials for more than an hour on Thursday. A six-minute report that opened Chinese state television’s evening news broadcast showed the businessmen listening intently, taking notes and applauding as Mr Xi decried protectionism and extolled the benefits of China’s One Belt, One Road programme and investment environment.
Pfizer Inc (NYSE:PFE) is trading with a trailing P/E of 9.9x, which is lower than the industry average of 24x. Although some investors may jump to the conclusion that thisRead More...
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
An experimental gene therapy appeared to dramatically increase the production of a muscle-making protein in three young boys with Duchenne muscular dystrophy, a deadly and irreversible disease, according to results being presented by the drugmaker Sarepta Therapeutics at an investor event this morning. “We think this has huge implications for the treatment of this disease,” says Jerry R. Mendell, the principal investigator in the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital, who is leading the study for Sarepta. “Being in this field doing clinical research for many years, I learned to be cautious,” says Ron Crystal, chairman of genetic medicine at Weill Cornell Medicine.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors.
On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.
The UK pharmaceuticals industry and the patients who rely on it are under serious threat from Brexit as well as from the flawed way medicines are developed, tested and made available to patients in the country. Leaders of our industry, which employs more than 140,000 people in the UK and contributes £30bn to gross domestic product, are meeting members of the government, including business secretary Greg Clark and international trade secretary Liam Fox, on Tuesday to discuss the country’s future as a world-leading life sciences hub. A report I compiled with PwC found that it remains a significant barrier to UK investment for many global companies.
The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding. The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point.
Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.
Investors continue to pour money into passive vehicles such as indexed mutual funds and exchange-traded funds. However, good old-fashioned stock picking and asset allocation with a human touch still rules in some areas - including in the well-trodden world of blue-chip stocks. After all, actively managed mutual funds run by professional portfolio managers still dwarf their passive cousins. At the end of 2017, actively managed funds had a total of $11.4 trillion in assets under management, according to Morningstar. Passive funds and ETFs controlled $6.7 trillion in assets. As we've noted before, the "smart money" doesn't always live up to the high fees and hype, but it's worth keeping tabs on what they're doing nonetheless. That's even more true for actively managed mutual funds. After all, they comprise a much larger swath of institutional investor dollars. Using data from Morningstar Direct, we were able to discover which blue-chip stocks are most widely held by the biggest actively managed U.S. mutual funds. In other words, these are the 25 most popular stock picks among professional portfolio managers. Not every one of the following stocks is necessarily a buy at current levels, but it's fair to say that they are all superstar companies. And the most popular pick of all probably will surprise you. SEE ALSO: 53 Best Dividend Stocks for 2018 and Beyond
Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.